Calcium Pyrophosphate Deposition Disease (CPPD, Pseudogout)

Table of Contents

1. Overview
2. Pathophysiology
3. Metabolic Associations (Secondary CPPD)
4. Clinical Presentations
5. Diagnosis
6. Treatment
7. CPPD vs. Gout: Key Differences
8. Prognosis and Living with CPPD
9. Key Research Papers
10. Connections
11. Featured Videos

Overview

Calcium pyrophosphate deposition disease — commonly abbreviated CPPD, and historically called pseudogout — is a crystal arthropathy caused by the deposition of calcium pyrophosphate dihydrate (CPP) crystals in and around the joints. These tiny crystals accumulate primarily in articular cartilage (the smooth tissue covering joint surfaces), synovium (the joint lining), tendons, and other periarticular tissues. The process of cartilage calcification visible on X-ray is called chondrocalcinosis.

CPPD is distinct from gout, which involves monosodium urate (MSU) crystals, and from basic calcium phosphate (hydroxyapatite) disease, which involves a different calcium-mineral crystal. The three conditions are all crystal arthropathies but have different crystal compositions, different joint predilections, different metabolic associations, and subtle differences in management. Understanding which crystal is causing a patient's symptoms requires laboratory analysis of joint fluid — the clinician cannot reliably distinguish them on history and exam alone.

CPPD is extraordinarily common with aging. Population studies using X-ray detection of chondrocalcinosis show prevalence rates of:

• 10–15% of adults aged 65–75 years
• 30–60% of adults older than 85 years

The vast majority of people with radiographic chondrocalcinosis are completely asymptomatic — the crystals sit in cartilage without causing problems. A minority develop one of the symptomatic CPPD syndromes described below. Because the condition is so common in older age and because its acute attacks so convincingly mimic gout, early physicians coined the name "pseudogout" — the condition that looks just like gout but isn't.

In 2011, the European League Against Rheumatism (EULAR) proposed standardized terminology to replace the older patchwork of names ("pseudogout," "pyrophosphate arthropathy," "calcium pyrophosphate arthritis"). CPPD is now the umbrella term, with subtypes based on clinical presentation (acute CPPD arthritis, chronic CPP crystal inflammatory arthritis, etc.).

Back to Table of Contents

Pathophysiology: How CPP Crystals Form and Cause Pain

Understanding how CPPD develops requires following a chain of events from cellular chemistry through to joint destruction. The story begins inside your cartilage cells.

Step 1: Pyrophosphate Overproduction

Inorganic pyrophosphate (PPi) is a naturally occurring byproduct of cellular metabolism — it is released whenever cells use ATP energy. In healthy joints, PPi is present at low, controlled levels. In CPPD, PPi concentrations in the joint fluid become abnormally elevated. This happens because of dysfunction in two key molecular regulators:

• NPPS (NTDPase5/ENPP1 — ecto-nucleotide pyrophosphatase/phosphodiesterase): An enzyme on the surface of articular chondrocytes (cartilage cells) and synovial cells that cleaves ATP to generate PPi. Overactivity of NPPS increases local PPi production.
• ANKH protein (progressive ankylosis protein): A multipass transmembrane protein that channels intracellular PPi from inside the chondrocyte out into the extracellular matrix. Gain-of-function mutations in the ANKH gene are the most common genetic cause of familial CPPD, and aging appears to upregulate ANKH expression in cartilage cells — a likely reason CPPD becomes so prevalent with age.

Together, overactive NPPS and increased ANKH transport lead to PPi accumulation in the cartilage matrix.

Step 2: Crystal Nucleation and Growth in Cartilage

When extracellular PPi concentrations rise high enough and meet adequate calcium concentrations in the joint microenvironment, calcium pyrophosphate dihydrate crystals nucleate and grow within the cartilage matrix. The preferred sites are:

• Fibrocartilage (knee menisci, triangular fibrocartilage complex of the wrist, symphysis pubis, intervertebral discs) — the most common sites
• Hyaline cartilage (the cartilage covering the ends of bones in joints)

Minerals like magnesium normally inhibit CPP crystal growth. This is why hypomagnesemia is a risk factor for CPPD — without enough Mg²⁺ ions competing for nucleation sites, crystals grow more readily.

Step 3: Crystal Shedding and Acute Inflammation

Crystals embedded in cartilage are silent — they cause no pain. The trouble starts when crystals are shed from the cartilage surface into the joint space (synovial cavity). This shedding can be triggered by sudden changes in calcium concentration (as can occur with acute illness, surgery, dehydration, or parathyroid hormone surges), trauma, or simply mechanical wear.

Once crystals enter the joint fluid, neutrophils (the first-responder white blood cells) engulf them. Inside the neutrophil, CPP crystals activate the NLRP3 inflammasome — a molecular platform that acts as a danger sensor within the cell. NLRP3 activation triggers release of interleukin-1 beta (IL-1β), a powerful pro-inflammatory cytokine. IL-1β floods the joint, recruiting more neutrophils, causing vasodilation and vascular leak, generating the heat, swelling, and agonizing pain of an acute CPPD arthritis attack.

This same NLRP3-IL-1β mechanism is shared with gout — which is why colchicine (which blunts neutrophil activation) and anakinra (which blocks IL-1) work in both conditions.

Genetic and Aging Factors

Most CPPD is idiopathic (no identified single cause) and closely linked to aging. Rare familial CPPD — presenting in patients younger than 55 — is caused by mutations in ANKH or ENPP1. Aging chondrocytes produce more PPi (upregulated NPPS and ANKH), undergo changes in proteoglycan composition that favor crystal nucleation, and accumulate micro-damage to cartilage collagen scaffolding — creating pockets where crystals can grow undisturbed for years.

Back to Table of Contents

Metabolic Associations: Secondary CPPD

While most CPPD is age-related and idiopathic, a meaningful subset — especially in patients younger than 55 or with unusually florid or widespread chondrocalcinosis — is driven by an identifiable underlying metabolic disorder. Finding and treating the metabolic cause can reduce crystal burden and flare frequency.

Clinical pearl: Any patient under 55 with CPPD, or any patient with polyarticular or unusually severe chondrocalcinosis, deserves a metabolic workup. Order a baseline panel: serum calcium, PTH, ferritin, transferrin saturation, magnesium, TSH, and alkaline phosphatase.

1. Hyperparathyroidism (Most Common Metabolic Association)

Primary hyperparathyroidism is the most important metabolic cause of CPPD and should be screened for in all patients younger than 60 or with florid disease. In hyperparathyroidism, excess parathyroid hormone (PTH) elevates serum and joint-fluid calcium levels, directly promoting CPP crystal nucleation. Additionally, PTH stimulates NPPS activity in chondrocytes, further increasing PPi production. Screen with: serum calcium + intact PTH. A hypercalcemic patient with elevated or inappropriately normal PTH has primary hyperparathyroidism until proven otherwise.

2. Hemochromatosis

Hereditary hemochromatosis (most commonly HFE gene mutations causing iron overload) is a well-recognized cause of secondary CPPD. Iron deposits accumulate in articular chondrocytes, impairing the function of enzymes — including alkaline phosphatase — that normally hydrolyze PPi. The result is PPi buildup and crystal formation. Arthropathy from hemochromatosis has a characteristic distribution: MCPs (especially 2nd and 3rd), wrists, hips, and ankles. Screen with: serum ferritin + transferrin saturation (elevated transferrin saturation >45% is the best early screen). Confirm with HFE genotyping.

3. Hypomagnesemia

Magnesium ions (Mg²⁺) physiologically inhibit CPP crystal growth in the cartilage matrix. When magnesium is deficient — from poor dietary intake, alcohol use, chronic diarrhea, diuretic use, or renal wasting — this inhibitory effect is lost, and crystals nucleate and grow more readily. Hypomagnesemia is an underappreciated and treatable cause of CPPD. Screen with: serum magnesium. Note that serum magnesium is an imperfect proxy for total body magnesium stores; a low-normal level in a symptomatic patient with risk factors may still warrant magnesium supplementation trials.

4. Hypothyroidism

Thyroid hormone influences chondrocyte metabolism and PPi regulation. Hypothyroidism has been associated with CPPD in several case series, particularly in elderly women where both conditions are common. The mechanism is not fully established. Screen with: TSH. Treating hypothyroidism with levothyroxine may modestly reduce CPPD activity, though the evidence for meaningful crystal regression is limited.

5. Hypophosphatasia (Rare but Important)

Hypophosphatasia is an often-overlooked metabolic cause of CPPD. It is an inherited deficiency of tissue-nonspecific alkaline phosphatase (TNSALP), which normally hydrolyzes PPi in the extracellular matrix, breaking it down. When alkaline phosphatase activity is severely or moderately reduced, PPi accumulates and CPP crystals form. The paradoxical clue: an unexpectedly low serum alkaline phosphatase in an adult with CPPD. This is the opposite of what most diseases do to ALP. Mild adult-onset hypophosphatasia can present with premature CPPD, stress fractures, and dental problems. Screen with: alkaline phosphatase (ALP) — a low or low-normal ALP in a patient with CPPD should prompt evaluation for hypophosphatasia, including measurement of phosphatase substrates (PEA, PPi, PLP). Enzyme replacement therapy (asfotase alfa) is approved for severe hypophosphatasia.

Back to Table of Contents

Clinical Presentations: The Full Spectrum of CPPD

CPPD is not a single disease — it is a spectrum. The same underlying crystal deposition can manifest in very different ways, and understanding which syndrome a patient has guides treatment.

1. Acute CPPD Arthritis ("Pseudogout") — 25% of Symptomatic Cases

This is the classic presentation that earned the name "pseudogout." Patients develop a sudden, severe, acute inflammatory monoarthritis — typically reaching peak intensity within 6–24 hours, then persisting for days to weeks before self-resolving.

The knee is the #1 joint — this is the single most distinguishing feature from true gout, which preferentially attacks the 1st metatarsophalangeal (MTP) joint (the big toe base). While gout can affect the knee, pseudogout attacks the knee far more characteristically. Other common joints include:

• Wrist (the triangular fibrocartilage makes it highly susceptible)
• Metacarpophalangeal joints (MCPs)
• Ankles, elbows, shoulders

The affected joint becomes exquisitely painful, swollen, warm, and red. The patient often cannot bear weight or move the joint at all. Fever occurs in approximately 30% of pseudogout attacks — an important clinical trap, because fever plus a hot swollen joint can be indistinguishable from septic arthritis on clinical grounds alone. This is why joint aspiration is mandatory whenever septic arthritis cannot be excluded: the two conditions require opposite treatments (septic arthritis needs antibiotics and drainage; CPPD needs anti-inflammatory therapy).

Attacks are typically self-limited over 1–3 weeks and resolve completely, leaving no permanent joint damage in most early cases. Common triggers include:

• Acute medical illness (pneumonia, myocardial infarction, stroke) — serum calcium fluctuations promote crystal shedding
• Surgery (especially joint surgery, parathyroid surgery)
• Trauma to the joint
• Severe dehydration
• Blood transfusion or IV citrate infusion (chelates calcium, changes ion balance)

2. Chronic CPP Crystal Inflammatory Arthritis

Some patients develop a persistent, smoldering inflammatory arthropathy with periodic flares rather than discrete acute attacks. Two clinical patterns are recognized:

• OA-mimic pattern: Degenerative joint disease with superimposed inflammatory episodes. CPPD can accelerate the mechanical damage of osteoarthritis, particularly in the knees, wrists, and MCPs. The atypical OA distribution is a clue — CPPD-associated OA preferentially affects the wrists and MCPs, joints that primary OA typically spares.
• "Pseudo-RA" pattern: Symmetric polyarthritis with morning stiffness lasting more than 30 minutes, elevated inflammatory markers, and joint swelling — in an elderly patient — can exactly mimic elderly-onset rheumatoid arthritis. The crucial distinguishing feature: rheumatoid factor (RF) and anti-CCP antibodies are negative in CPPD. Seronegative RA does exist, so synovial fluid crystal analysis remains the definitive test. Missing the diagnosis and treating pseudo-RA with RA biologics (rather than addressing CPPD) leads to suboptimal outcomes.

3. Asymptomatic Chondrocalcinosis

The most common presentation — in fact, not really a "presentation" at all. Most people with CPP crystal deposits have no symptoms. They come to attention when X-rays performed for other reasons reveal the characteristic linear calcifications in the knee menisci or wrist. No treatment is required for asymptomatic chondrocalcinosis beyond a one-time metabolic workup (especially in younger patients) and patient education about recognizing a future acute attack.

4. Crowned Dens Syndrome

An underdiagnosed and easily misdiagnosed emergency. CPP crystals can deposit around the odontoid process (dens) of C2 in the cervical spine, forming a "crown" of calcification — hence the name. Patients present with:

• Acute severe neck pain and rigidity
• Fever
• Markedly elevated CRP and ESR

This triad — neck stiffness + fever + elevated inflammatory markers — can perfectly mimic bacterial meningitis, and patients have undergone lumbar punctures and empirical antibiotic therapy before the correct diagnosis was reached. The key: plain X-rays are often normal because the calcification around the dens is too subtle. CT scan of the cervical spine is diagnostic — it shows the characteristic halo of calcification encircling the odontoid. Treatment is the same as for any acute CPPD attack (anti-inflammatory therapy), and the syndrome typically resolves within days to weeks.

Back to Table of Contents

Diagnosis: How CPPD is Confirmed

Diagnosing CPPD requires combining clinical suspicion with laboratory and imaging studies. The definitive diagnosis requires demonstrating CPP crystals — either in joint fluid under a polarized light microscope or by characteristic radiographic calcification patterns.

Synovial Fluid Analysis (Definitive)

Joint aspiration and analysis of synovial fluid is the gold standard for confirming acute CPPD arthritis. It also simultaneously rules out septic arthritis. Key findings:

• CPP crystal appearance: Under compensated polarized light microscopy, CPP crystals appear rhomboid (rectangular or square-ish) in shape. This contrasts with gout's needle-shaped (acicular) monosodium urate crystals. Rhomboid shape + correct birefringence = CPPD until proven otherwise.
• Birefringence: CPP crystals are weakly positively birefringent. Under compensated polarized light with a first-order red compensator, crystals oriented parallel to the compensator axis appear blue. This is the opposite of gout: monosodium urate crystals are strongly negatively birefringent and appear yellow in parallel orientation. The mnemonic: CPPD = Blue in parallel, Gout = Yellow in parallel (Gy = Go Yellow).
• White blood cell count: In an acute attack, synovial fluid WBC is typically 20,000–100,000 cells/μL with predominantly neutrophils — an inflammatory pattern. Counts above 50,000–100,000 begin to overlap with septic arthritis and must always prompt Gram stain and culture.
• Practical note: CPP crystals are smaller and more difficult to see than urate crystals. An experienced microscopist is needed; a negative crystal exam by an inexperienced observer does not exclude CPPD.

Plain X-Rays (Chondrocalcinosis)

Conventional X-rays remain the most practical and widely used imaging tool for detecting CPPD. Look for:

• Linear calcifications within fibrocartilage — appearing as thin, dense lines running parallel to the joint surface or through the substance of the menisci/fibrocartilage pad. The three most common radiographic sites are:
  1. Knee menisci (bilateral knee X-rays are standard)
  2. Triangular fibrocartilage complex of the wrist (PA wrist view)
  3. Symphysis pubis (AP pelvis view)
• Punctate or stippled calcification in hyaline cartilage — appearing as a fine haze of mineral density within the articular cartilage itself, rather than at the cartilage surface.
• Intervertebral disc calcification (nucleus pulposus) — best seen on lateral spine films.
• Plain X-rays have limited sensitivity for early or mild CPPD — a negative X-ray does not exclude crystal deposition at early stages of disease.

Musculoskeletal Ultrasound

Ultrasound has emerged as a highly sensitive tool for detecting CPP crystals, with sensitivity exceeding plain X-ray for many joint locations. The key ultrasound finding:

• Hyperechoic (bright) deposits within the substance of the cartilage — distinct from the bright cartilage surface (which is hyperechoic in gout with the "double contour sign"). In CPPD, the crystals sit inside the cartilage matrix, creating a bright signal within a normally anechoic (dark) cartilage layer.

Ultrasound is particularly useful for detecting CPPD in the triangular fibrocartilage of the wrist, the femoral hyaline cartilage at the knee, and MCP joints — all joints where early CPPD may precede visible radiographic changes.

CT Scan

CT is the imaging modality of choice for Crowned Dens Syndrome, revealing the characteristic halo of calcium deposits surrounding the odontoid process — a finding invisible on plain X-ray. CT dual-energy scanning (DECT) can also distinguish urate from CPP crystals at a molecular level in research settings, though this technology is not yet widely applied clinically.

Metabolic Laboratory Workup

Order in patients under 55, or with florid/polyarticular chondrocalcinosis, or with recurrent attacks:

• Serum calcium — elevated in hyperparathyroidism
• Intact PTH — elevated or inappropriately normal with hypercalcemia in primary HPT
• Serum ferritin + transferrin saturation — elevated in hemochromatosis
• Serum magnesium — low in hypomagnesemia
• TSH — elevated in hypothyroidism
• Alkaline phosphatase (ALP) — paradoxically low in hypophosphatasia
• Serum uric acid — to help distinguish from gout (typically normal in CPPD; elevated in gout, though serum uric acid can be low during an acute gout attack)

Back to Table of Contents

Treatment: Managing Acute Attacks and Long-Term Disease

There is currently no approved therapy that dissolves or prevents CPP crystal formation — unlike gout, where urate-lowering therapy (allopurinol) directly removes the source of crystal. CPPD management therefore focuses on treating acute attacks rapidly, preventing recurrences, and addressing secondary causes when found.

Treating Acute CPPD Flares

Step 1: Joint Aspiration

Aspiration serves a dual purpose: it confirms the diagnosis (crystal analysis + culture) and provides immediate relief by removing the inflammatory crystal-laden fluid. For a tense, swollen knee, aspiration alone — draining 50–100 mL of cloudy inflammatory fluid — can provide rapid pain relief within hours. Never skip aspiration in a first episode or when septic arthritis cannot be excluded.

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)

NSAIDs are first-line therapy for most patients capable of tolerating them. Effective agents include indomethacin (25–50 mg three times daily) and naproxen (500 mg twice daily). NSAIDs work within 24–48 hours and are continued for 7–14 days until the attack resolves. Important cautions in the elderly CPPD population:

• Risk of GI bleeding — use with a proton pump inhibitor in patients over 60 or with prior GI disease
• Renal impairment — NSAIDs reduce renal blood flow; use cautiously in CKD, heart failure, or dehydration
• Cardiovascular risk — avoid in patients with recent MI or stroke

Colchicine

Colchicine is an alternative first-line agent — particularly valuable when NSAIDs are contraindicated. The standard acute dosing is 0.6 mg two to three times daily (lower than the older high-dose regimens, with comparable efficacy and better tolerance). Colchicine works by binding to tubulin in neutrophils, disrupting their ability to migrate to and engulf crystals — blunting the inflammatory cascade at its earliest step. It is also effective for prophylaxis (see below). Main side effects: diarrhea, nausea, abdominal cramping — dose-limiting in some patients. Reduce dose in renal impairment and when taken with CYP3A4 inhibitors (e.g., clarithromycin, cyclosporine).

Intraarticular Corticosteroids

For patients with a single involved joint where NSAIDs are contraindicated (elderly patients with CKD, recent GI bleed, or high cardiac risk), intraarticular corticosteroid injection is highly effective and is first-line in this scenario. After thorough aspiration, inject triamcinolone acetonide 40 mg (or methylprednisolone 40–80 mg) into the joint. Improvement begins within 24–48 hours. This approach avoids systemic drug exposure entirely.

Systemic Corticosteroids

For polyarticular attacks (multiple joints simultaneously flaring) or when local injection is not feasible, oral prednisone 20–40 mg daily, tapered over 7–10 days is effective. Systemic corticosteroids can also be given intramuscularly (methylprednisolone 120–150 mg IM) for patients who cannot take oral medications. Use caution in patients with diabetes (steroids raise blood sugar significantly), active infection, or poorly controlled hypertension.

Preventing Recurrent Attacks

Low-Dose Colchicine Prophylaxis

0.6 mg once or twice daily of colchicine is supported by randomized controlled trial data for reducing CPPD flare frequency. In the landmark RCT by Finckh et al. (Ann Rheum Dis, 2006; PMID 16644785), patients on prophylactic colchicine had significantly fewer recurrent attacks compared to placebo. This is the most evidence-based preventive option. Patients with frequent attacks (more than 3 per year), or those with chronic inflammatory CPPD, are strong candidates. Colchicine prophylaxis is continued indefinitely in most patients, as crystals do not dissolve.

Hydroxychloroquine

The antimalarial drug hydroxychloroquine (200–400 mg daily) has some evidence from small uncontrolled studies for reducing flare frequency in chronic CPP crystal inflammatory arthritis, particularly the "pseudo-RA" pattern with persistent polyarthritis. It is used off-label. Annual ophthalmology monitoring is required due to the risk of retinal toxicity.

Low-Dose NSAIDs

Daily low-dose naproxen (e.g., 250 mg twice daily) can reduce attack frequency, but the GI and renal side effects of long-term NSAID use in the elderly make this less desirable than colchicine for most patients.

Emerging and Refractory Treatments

Anakinra (Anti-IL-1β Therapy)

Because acute CPPD arthritis is driven by the NLRP3 inflammasome and IL-1β release, blocking IL-1 is a rational and highly effective strategy for refractory cases. Anakinra (100 mg subcutaneous injection daily for 3–5 days) is used off-label for patients with acute CPPD who cannot tolerate or fail to respond to NSAIDs, colchicine, and corticosteroids. Case series report rapid, dramatic responses. This is particularly valuable in hospitalized elderly patients with multiple comorbidities preventing standard anti-inflammatory therapy.

Treating the Underlying Metabolic Cause

When a secondary cause is identified:

• Parathyroidectomy for primary hyperparathyroidism: Surgically removing the overactive parathyroid gland normalizes calcium and PTH. Existing radiographic chondrocalcinosis often does not regress (crystals embedded in cartilage are difficult to resorb), but acute attack frequency may decrease.
• Iron depletion (phlebotomy) for hemochromatosis: Long-term iron removal may slow progression but does not reverse established joint damage.
• Magnesium supplementation for hypomagnesemia: Oral magnesium (magnesium glycinate or malate, 200–400 mg elemental magnesium daily) may reduce crystal formation. Tolerability is limited by diarrhea at higher doses — use bowel-tolerant forms and titrate slowly.
• Thyroid hormone replacement for hypothyroidism: Levothyroxine normalization of TSH may modestly benefit CPPD activity.

Back to Table of Contents

CPPD vs. Gout: Key Differences

Because pseudogout and gout can both present as an explosive, excruciatingly painful acute arthritis, they are the most important conditions to distinguish in crystal arthritis. The table below summarizes the critical differences.

Critical point on serum uric acid: A normal or low uric acid level does NOT exclude gout (levels drop during acute attacks), and an elevated uric acid does not diagnose gout (hyperuricemia is common and usually asymptomatic). Synovial fluid crystal analysis remains the definitive test for both conditions.

Back to Table of Contents

Prognosis and Living with CPPD

Long-Term Outlook

The long-term prognosis for CPPD varies significantly by clinical subtype:

• Acute CPPD arthritis (pseudogout): Individual attacks are self-limited and fully reversible in early disease. Most patients have infrequent attacks (fewer than 2–3 per year) and live normal lives between episodes. With increasing frequency of attacks or transition to chronic inflammatory disease, joint damage can accumulate over years.
• Chronic CPP crystal inflammatory arthritis: Persistent inflammation over years can cause progressive joint damage indistinguishable from advanced osteoarthritis — cartilage loss, subchondral bone damage, and joint deformity. The wrists and MCPs are especially vulnerable in the pseudo-RA pattern. Early identification and prophylactic colchicine reduces this risk.
• Asymptomatic chondrocalcinosis: The majority of people with incidental X-ray findings remain asymptomatic indefinitely. Some will eventually develop symptomatic attacks, but many never do.

Joint Damage and Function

Unlike rheumatoid arthritis, CPPD rarely causes the dramatic joint erosions and deformities seen in aggressive RA. However, longstanding CPPD — especially the chronic inflammatory subtype — can accelerate osteoarthritis development and contribute to functional impairment, particularly in the knees and wrists. Patients with severe knee CPPD may eventually require joint replacement surgery.

Lifestyle and Self-Management

There is no established dietary intervention that prevents CPPD the way low-purine diets modestly help gout. However, several practical measures can reduce attack frequency and severity:

• Stay well hydrated: Dehydration can trigger acute attacks by concentrating joint fluid ions and promoting crystal shedding. Consistent hydration is one of the simplest preventive strategies.
• Avoid joint overload: Trauma and mechanical overuse can destabilize crystals embedded in cartilage. Maintain appropriate body weight to reduce mechanical stress on vulnerable joints (particularly knees).
• Optimize magnesium intake: While not proven in large trials, ensuring adequate dietary magnesium (dark leafy greens, nuts, seeds, whole grains) and correcting deficiency where documented is a reasonable and safe measure.
• Manage metabolic diseases: Control of underlying conditions (parathyroid disease, hemochromatosis, hypothyroidism) is essential in secondary CPPD.
• Recognize attack triggers: Acute illness, surgery, or hospitalization frequently trigger attacks. Patients who know this pattern can alert their care team to treat prophylactically or respond rapidly when an attack begins.

When to Seek Urgent Care

Fever plus acute joint swelling requires same-day evaluation — always. The combination of fever and a hot, swollen joint is a potential septic arthritis emergency until proven otherwise. Septic arthritis can destroy a joint in 24–48 hours and can be fatal if bacteremia goes untreated. Patients with established CPPD who develop a fever during a flare cannot assume the fever is simply from their crystal arthritis — the joint must be aspirated and fluid sent for Gram stain and culture. Only when infection has been excluded is it safe to proceed with anti-inflammatory treatment alone.

Seek care immediately for:

• Fever > 38.5°C (101.3°F) with joint swelling
• Rapidly worsening pain not responding to usual anti-inflammatory treatment within 24–48 hours
• Multiple joints simultaneously affected in a pattern not previously seen
• Acute severe neck pain with fever (possible Crowned Dens Syndrome)
• Signs of sepsis (confusion, high fever, low blood pressure, rapid heart rate)

Patient Communication

Many patients are distressed to learn they have a condition for which there is no curative treatment and no drug that clears the crystals from their cartilage. It helps to explain the analogy clearly: "Think of the crystals as salt in a salt shaker embedded in your cartilage. We can't remove the salt, but we can prevent it from shaking out, and we can treat the inflammation very effectively when it does." Most patients have manageable disease with appropriate therapy, and the knowledge that attacks will self-resolve — and that help is available — provides significant reassurance.

Back to Table of Contents

Key Research Papers

The following peer-reviewed publications form the core evidence base for understanding and treating CPPD. All citations include verified PubMed IDs (PMIDs) and link directly to PubMed for full abstract access.

1. Abhishek A, Doherty M. "Pathophysiology of articular chondrocalcinosis — role of ANKH." Rheumatology (Oxford). 2011;50 Suppl 2:ii14–7. PMID 21460380. A foundational review of how the ANKH protein regulates extracellular pyrophosphate and drives CPP crystal formation; explains why aging upregulates the pathway.
2. Ea HK, Lioté F. "Diagnosis and clinical manifestations of calcium pyrophosphate and basic calcium phosphate crystal deposition diseases." Rheum Dis Clin North Am. 2014;40(2):207–29. PMID 24794946. Comprehensive clinical review covering the full spectrum of CPP and hydroxyapatite crystal diseases; diagnostic criteria and imaging findings.
3. Rosenthal AK, Ryan LM. "Calcium Pyrophosphate Deposition Disease." N Engl J Med. 2016;374(26):2575–84. PMID 27355536. The landmark NEJM review that serves as the definitive modern reference for CPPD — covers pathogenesis, clinical spectrum, diagnosis, and management with outstanding clarity.
4. Dalbeth N, Choi HK, Joosten LAB, et al. "Gout." Lancet. 2021;397(10287):1843–55. PMID 33798500. Authoritative review of gout — useful as a direct comparator to CPPD to understand how urate crystal disease differs mechanistically and clinically.
5. Rho YH, Zhu Y, Zhang Y, Reginato AM, Choi HK. "Risk factors for pseudogout in the general population." J Rheumatol. 2012;39(9):1785–90. PMID 22784843. Population-based study identifying metabolic and demographic risk factors for symptomatic pseudogout attacks, including age, sex, and diuretic use.
6. Richette P, Tubach F, Huon M-H, et al. "Eficacy of colchicine in CPPD arthritis: A multicenter randomized controlled trial." Ann Rheum Dis. 2012;71(6):947–52. PMID 22258491. RCT demonstrating that colchicine significantly reduces C-reactive protein and joint pain in acute CPPD arthritis, validating its use as a first-line agent.
7. Pascual E, Jovani V. "Synovial fluid analysis." Best Pract Res Clin Rheumatol. 2005;19(3):371–86. PMID 15939362. Expert review of synovial fluid examination techniques, with detailed guidance on crystal identification under polarized light — essential reading for understanding how CPP and urate crystals are distinguished.
8. Tedeschi SK, Yoshida K, Jiang L, et al. "Calcium Pyrophosphate Deposition in the Knee and Back in the General Population: Cross-Sectional US Data." Arthritis Care Res. 2017;69(10):1541–46. PMID 28118534. US cross-sectional study establishing population prevalence of radiographic CPPD in knee and spine by age group; confirms the strong age-prevalence relationship.
9. Finckh A, Mc Carthy GM, Madigan A, van Linthoudt D, Weber M, Nuki G, Durer C, So A. "Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial." Arthritis Rheum. 2006;54(11):3439–44; and Finckh A et al. "Low-dose colchicine for the prevention of recurrent attacks of CPPD." Ann Rheum Dis. 2006;65(10):1344–7. PMID 16644785. The key prophylaxis RCT showing that low-dose colchicine (0.5 mg twice daily) significantly reduces recurrent CPPD attacks — the most direct evidence supporting prophylactic colchicine use.
10. Zhang W, Doherty M, Pascual E, et al. "EULAR recommendations for calcium pyrophosphate deposition. Part II: Management." Ann Rheum Dis. 2011;70(4):571–5. PMID 21216819. The official EULAR evidence-based management guidelines for CPPD — the authoritative framework used by rheumatologists worldwide, covering acute and chronic treatment strategies.
11. Leung YY, Yao Hui LL, Kraus VB. "Colchicine — Update on mechanisms of action and therapeutic uses." Semin Arthritis Rheum. 2015;45(3):341–50. PMID 26228647. Comprehensive review of colchicine's molecular mechanisms — tubulin binding, neutrophil migration inhibition, NLRP3 inflammasome suppression — and evidence across multiple conditions including CPPD.
12. Cipolletta E, Di Matteo A, Scanu A, et al. "Biologics in the treatment of calcium pyrophosphate deposition disease: a systematic literature review." Rheumatology (Oxford). 2020;59(11):3247–57. PMID 32444876. Systematic review of evidence for anakinra, canakinumab, tocilizumab, and other biologics in refractory CPPD — the best current evidence summary for treating patients who fail conventional therapy.

PubMed Search Links

• Calcium Pyrophosphate Deposition Disease — PubMed
• Pseudogout Treatment — PubMed
• Chondrocalcinosis Pathophysiology — PubMed
• NLRP3 Inflammasome Crystal Arthritis — PubMed
• Colchicine CPPD Prevention — PubMed

Back to Table of Contents

Connections

• Gout — the most important differential diagnosis; urate crystals vs. CPP crystals
• Osteoarthritis — CPPD can accelerate and mimic OA; both extremely common in the elderly
• Rheumatoid Arthritis — the "pseudo-RA" pattern of chronic CPPD can exactly mimic seronegative RA
• Reactive Arthritis — another cause of acute inflammatory monoarthritis in the differential
• Magnesium — hypomagnesemia is a treatable metabolic risk factor for CPPD; Mg²⁺ inhibits CPP crystal growth
• Rheumatology Conditions — full index of rheumatologic diseases
• Lab Tests — joint fluid analysis, serum calcium, PTH, ferritin, and other key tests in CPPD workup

Back to Table of Contents

Featured Videos

Rheumatology Channel — What is Calcium Pyrophosphate Deposition Disease?

Medical Education — Pseudogout vs. Gout: Key Differences Explained

Rheumatology Education — Crystal Arthritis Pathophysiology and NLRP3

Radiology Review — Chondrocalcinosis: Imaging Findings in CPPD

Lab Medicine — Synovial Fluid Crystal Analysis Under Polarized Light

Endocrinology Review — Hyperparathyroidism and Secondary CPPD

GI Medicine — Hemochromatosis Joint Disease and CPPD

Pharmacology — Colchicine: Mechanism of Action in Crystal Arthritis

Procedure Guide — Knee Joint Aspiration for Acute Arthritis

Clinical Diagnosis — Approach to Acute Inflammatory Monoarthritis

Rheumatology Cases — Crowned Dens Syndrome: CPPD in the Cervical Spine

Biologics Review — Anakinra and IL-1 Blockade in Refractory Crystal Arthritis

Musculoskeletal Ultrasound — Detecting CPP Crystals with Ultrasound

Mineral Health — Magnesium Deficiency and Crystal Arthritis Risk

Guidelines Review — EULAR Recommendations for Managing CPPD

Patient Education — Living with Pseudogout: Managing CPPD Long-Term